듀켐바이오

176750KOSDAQ의약품 제조업

54.3 / 100

Reference Date: 2026-07-24

Financial Score15.0 / 40

News Sentiment21.3 / 25

Momentum8.0 / 20

Disclosure10.0 / 15

AI Analysis: ROE significantly exceeds the industry average but PER raises overvaluation concerns. Declined 12.6% over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

Dukem Bio is a company specializing in the development, manufacturing, and sales of radiopharmaceuticals for cancer and brain diseases, holding the largest number of PET-CT radiopharmaceutical products in South Korea. In 2025, it achieved revenue of 38.57 billion won and operating profit of 7.44 billion won, maintaining a market share leadership in key product lines such as FDG and Alzheimer's diagnostic agents. By acquiring RadioDnS Labs in 2024, the company is enhancing its R&D capabilities and aiming to become a global leader in radiopharmaceuticals.

Number of Employees

144people

Average Salary

44.5M KRW

Score Calculation Basis

Detailed Financial Score

PER

24.59Industry Average 11.230.0Point

2.2x industry avg (risky)

PBR

3.26Industry Average 0.810.0Point

4.0x industry avg (risky)

ROE

14.05Industry Average 4.017.0Point

3.5x industry avg (excellent)

Debt Ratio

20.42Industry Average 12.430.5Point

1.6x industry avg (risky)

Trend 2024~20257.5 / 10 points

Revenue Growth Rate

2.0 / 3

Avg ▲8.3% (1-year basis)

Operating Profit Growth Rate

3.0 / 3

Avg ▲46.6% (1-year basis)

ROE Trend

2.5 / 4

Avg ROE 19.4% (declining, 2yr)

Detailed News Sentiment

3 totalPositive 3Neutral 0Negative 0Average Sentiment Score 85

Positive
듀켐바이오, 자회사 라디오디앤에스랩스와 합병
듀켐바이오의 라디오디앤에스랩스 합병으로 기술 역량 강화 및 신규 인재 영입으로 긍정적 전망.
Positive
진단 넘어 치료용 방사성약으로…듀켐바이오, R&D 자회사 합친다
듀켐바이오가 방사성의약품 R&D 자회사를 합병하여 치료용 방사성의약품 개발 역량을 강화하고 효율성을 향상시킬 것으로 기대됩니다.
Positive
듀켐바이오, R&D 자회사 합병…"CDMO 역량 갖춰"
듀켐바이오의 기술 역량 강화를 위한 라디오디앤에스랩스 합병으로 인해 기술 리더십 확보 및 혁신적 성장 기대.

Detailed Momentum

52-week position1.0Point

Near 52w low (0%, downtrend)

Current 5,630Won52-week high 11,68052-week low 5,620

1-month return1.0Point

1m -12.58% (falling)

Volume trend6.0Point

Volume surge

Detailed Disclosure

4 totalPositive 0Neutral 4Negative 0

Neutral[첨부정정]주요사항보고서(회사합병결정)2026-07-23
Neutral[첨부정정]주요사항보고서(회사합병결정)2026-07-23
Neutral주주명부폐쇄기간또는기준일설정2026-07-22
Neutral주요사항보고서(회사합병결정)2026-07-22